# A Study of NGM282 in Patients With Primary Sclerosing Cholangitis

> **NCT02704364** · PHASE2 · COMPLETED · sponsor: **NGM Biopharmaceuticals, Inc** · enrollment: 62 (actual)

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **BIOLOGICAL:** NGM282
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02704364
- **Lead sponsor:** NGM Biopharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02704364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02704364, "A Study of NGM282 in Patients With Primary Sclerosing Cholangitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02704364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*